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Abstract 
This randomized, open sequential design trial was set up to assess the efficacy, tolerability and toxicity of 20 d 
courses of combined intramuscular aminosidine and sodium stibogluconate at various dosages in patients 
with newly-diagnosed kala-azar in Bihar, India. Three successive studies of 96 patients each were originally 
planned with aminosidine administered at 12,6 and 3 mgikgid, respectively. For each aminosidine dosage, 
patients were randomly assigned to receive sodium stibogluconate at 20, 10 or 5 mgikgld of antimony. 
Ninety-six patients were enrolled and assigned aminosidine 12 mgikgid as scheduled. In the subsequent 
study with aminosidine at 6 mgikgid, the trial was interrupted after 40 patients had entered owing to inade- 
quacy of the treatment. With aminosidine 12 mgikgld the success rates with sodium stibogluconate at 20, 10 
and 5 mg/kg/d were 88%, 71% and 72%, respectively and did not differ significantly. With aminosidine 6 
mgikgid, 69%, 50% and 46% of patients were cured with the same sodium stibogluconate doses, respec- 
tively; again, there was no significant difference between the subgroups. The overall success rate with ami- 
nosidine at 12 mgikgid (76%) was significantly higher than that with 6 mgikgid (55%) (odds ratio=2.69; 
95% confidence interval, 1.1 l-6.4). Patients improved clinically and the treatments were equally well tol- 
erated. The combination of aminosidine 12 mgikgid and sodium stibogluconate 20 mg/kg/d for 20 d appears 
to be an effective and safe replacement in Bihar for sodium stibogluconate alone for ~40 d. 
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Introduction 
Response to treatment with organic pentavalent anti- 
monials, the standard first-line treatment for kala-azar 
(visceral leishmaniasis), has been decreasing over the 
years in India (INDIA, 1991; THAKUR, 1993). Several 
papers have reported prolonging courses and increasing 
dosages in an attempt o compensate for diminishing ac- 
tivity (PETER, 1981; THAKUR, 1984; THAKUR et al., 
1988, 1991). Now there is hardly any patient with kala- 
azar m Bihar who needs fewer than 40 d of sodium stibo- 
gluconate at 20 mgikgid. Despite such prolonged treat- 
ment, the success rate is at present only slightly above 
80% and it is well below 70% after 3 weeks of treatment. 
However, adverse reactions are seen more frequently and 
costs have increased dramatically (THAKUR et al., 1991; 
OLLIARO & BRYCESON, 1993). 
It is therefore necessary to increase efficacy and also 
reduce the total drug intake. A probable solution seemed 
to be combining sodium stibogluconate with amino- 
sidine, which is available as an injectable formulation 
(Gabbromycin@, Farmitalia Carlo Erba). Aminosidine is 
an aminoglycosidic aminocyclitol antibiotic belonging to 
the 2-deoxystreptamine subgroup (ARCAMONE et al., 
1975). Identity of the catenulin-neomycin antibiotics, in- 
cluding aminosidine and paromomycin, produced by dif- 
ferent Streptomyces species, was first recognized by 
SCHILLING & SCHAFFN’ER (1961). Although the anti- 
leishmanial properties of paromomycin (=aminosidine) 
were first shown by NEAL in 1968, only recently was the 
drug used in patients with kala-azar (CHUNGE et al., 
1990). As this study indicated that the combination of 
aminosidine and sodium stibogluconate was superior to 
either drug alone, we did a pilot study to assess the appli- 
cabilitv of those results to Indian kala-azar (THAKUR et 
al., 1992); a 20 d course of aminosidine at ‘12 mgik id 
and sodium stibogluconate at 20 mglkgid was 82% ef ec- B 
tive and was well tolerated. The efficacy of combined 
regimens of aminosidine and antimony has been further 
documented in visceral leishmaniasis due to Leishmania 
donovani and disseminated cutaneous leishmaniasis due 
to L. aethio 
P 
ica by SEAMAS et al. (1993) and TEKLEMA- 
RIAM et al. 1994). 
A dose-finding study was therefore set up to confirm 
these encouraging results and to assess the efficacy and 
safety of different ratios of aminosidine and sodium sti- 
bogluconate. 
Address for correspondence: P. Olliaro, TDR, World Health 
Organization, 1211 Geneva 27, Switzerland. 
Methods 
Study design and treatment schedules 
This was a randomized, open, sequential-design trial. 
The protocol received ethical clearance by the Indian 
Drug Controller and the local Ethical Committee. After 
giving informed consent, patients were enrolled, ad- 
mitted to hospital and treated at Tripolia Social Service 
Hospital, Patna, Bihar, India. The study drugs were 
aminosidine (Gabbromycin@, Farmitalia Carlo Erba, Mi- 
lano, Italy) and sodium stibogluconate (Stibanatea, The 
Gluconate Ltd, Calcutta, India). 
The trial was designed to include 3 successive groups 
of 96 patients, each receiving aminosidine at 12 mgikgid 
(group l), 6 mgikgid (group 2), or 3 mgikgid (group 3), 
but the last dosage was not used (see below). Within each 
study, patients were randomly assigned to 3 subgroups 
receiving 20 mgikgid (subgroup a), 10 mg/kg/d (sub- 
group b), or 5 mgikgid (subgroup c) of sodium stiboglu- 
conate. The efficacy of each treatment schedule was to be 
assessed on the basis of the response rate (p), defined as 
the proportion of patients with negative spleen aspirate at 
the end of therapy (day 21). The treatment was to be 
considered ineffective if p sO.65. Assuming an (Y level of 
0.05 and a power (1-p) of 0.8 to detect paO.85, it was 
calculated that 32 patients were required for each dose 
combination. The trial was to start with patients assigned 
to aminosidine at 12 mgikgid (group 1 j. If a group-was 
successfullv treated, a further grotto of 32 natients was to 
be enrolled and treated with the same dose of sodium sti- 
bogluconate and half the dose of aminosidine (i.e., 6 
mgikgid; group 2). Assignment to the sodium stiboglu- 
conate dose within each trial (subgroups a, b or c) was 
randomized. 
Both drugs were administered intramuscularly at dif- 
ferent sites for 20 d. Patients were admitted to hospital 
the dav before treatment and remained in hosnital for 20 
d treatment and post-treatment assessment on day 21. 
Follow-up visits were scheduled for 90 d and 180 d after 
the end of treatment. 
Patients 
Only patients with previously untreated kala-azar, di- 
agnosed by finding amastigotes in splenic aspirate and 
the presence of typical clinical signs and symptoms of 
kala-azar were included. All patients came from the same 
f 
eographical area of India (Vaishali, Samastipur, Musaf- 
arpur and Patna districts). 
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Clinical and laboratoy examinations 
Clinical and laboratory investigations were carried out 
before starting treatment (baseline values), on days 7 and 
14 during treatment, one day after end of treatment (day 
21), and during the drug-free follow-up period on days 
90 and 180. The examinations included: (i) splenic aspir- 
ate to assess parasite load according to CHULAY & 
BRYCESON (1983) and measurement of spleen and liver 
size (from costal margin along the anterior axillary line); 
Clinical laboratory values were classified as normal or 
abnormal according to whether they were within or out- 
side the normal ranges. To assess the direction of changes, 
the paired observations of values classified as described 
above were analysed at the baseline and on day 21 by 
using x2 or Fisher’s exact two-tailed test (as appropriate) 
for each treatment group. A stratified analysis was also 
conducted within each phase and the Mantel-Haenszel 
weighted OR and 95% CI were calculated. 
(ii) body weight and body temperature; (iii) white blood 
cell (WBC) counts and haemoglobin determination; and 
All results were assessed at a significance level of 
P=O.O5. 
(iv) other haematological and blood chemistry tests, in- 
cluding liver and renal function tests. Electrocardio- Results 
graphy (ECG) and audiometry were scheduled before 
and after treatment. 
Aminosidine at 12 mglkgld (group I) 
The 3 subgroups did not differ with respect to demo- 
Table 1. Baseline characteristics of kala-azar patients treated with aminosidine and sodium stibogluconate 
Aminosidine dosage 
12 mglkgld 
Mean SD Range Mean 
6 mglkgld 
SD Ranee 
A e (years) 
Y& elaht (kg) 
24.8 14.1 5-67 22.5 14.9 6-66 
37.8 13.4 1 l-72 33.2 12.2 12-56 
Tenipe&t&e (“C) 
Parasite grading 
Spleen size (cm) 
Liver size (cm) 
Haemoglobin (g/dL) 
White blood cells (x 1000/mm3) 
37.2 ;:; 36xo 
37.8 1.4 36.7-39.4 
1.3 l-6 ;:; 3.4 2-16 ;:; 3 2-15 
2 O-10 4.1 1.9 l-8 ;:; 
2.2 3-12.4 8.7 3.8-11.6 
3436.6 1280.7 1350-8000 3758.8 135:i 1050-6800 
Efficacy graphic or baseline characteristics (Table 1). 
Effective treatment was defined as a negative splenic 
aspirate at the end of therapy (day 21). Upon discharge, 
patients were advised to report for follow-up on days 90 
and 180 to monitor the occurrence of relapses and late 
cures. However, only a descriptive analysis was possible 
at follow-up due to the low numbers of patients repor- 
ting. 
Test of cure. Treatment la gave the highest proportion 
of patients with negative splenic aspirate at the end of 
therapy, though the result was not statistically signifi- 
cantly superior to those obtained in the other groups 
(Table 2). The proportion of patients with a negative 
splenic aspirate increased with the length of treatment 
with all 3 regimens (Table 2). 
Table 2. Success rates (conversion from positive to negative splenic aspirate) for kala-azar patients treated with 
aminosidine and sodium stibogluconate 
Subgroup aa 
No. of negative patients/no. examined 
Subgroup b” Subgroup ca Total 
Aminosidine dosage 
liayey$/d (grow 1) 
Day 7 
Day 14 
Day 21 
0132 O/32 0132 O/96 
6132 (19%) 10132 (31%) 6132 (19%) 22196 (23%) 
18/32 (56%) 17132 (53%) 17132 (53%) 52196 (54%) 
28/32 (88%) 22/31 (71%) 23132 (72%) 73195 (76%) 
6 mgikgid (group 2) 
Baseline 0113 0113 o/14 O/40 
Day 7 1113 (8%) 2113 (15%) 1113 (8%) 4139 (10%) 
Day 14 3110 (30%) 4111 (36%) 3113 (23%) 10134 (29%) 
Day 21 9113 (69%) 6112 (50%) 6113 (46%) 21/38 (55%) 
aSodium stibogluconate dosages: subgroup a, 20 mglkgid; subgroup b, 10 mgikgld; subgroup c, 5 mgikgid. 
Parasite load decreased in all patients but one in group 
Data handling and analyses lb; no significant difference was apparent between the 
Data were recorded on individual case record forms, subgroups. 
entered into a Lotus@ 123 computer package, verified Overall, 47 (49%) and 26 (27%) patients reported for 
and checked, and then transferred to EpiInfo for ana- follow-up visits on days 90 and 180, respectively. Of 
lysis. these, 38 and 21 had been classified as treatment suc- 
The proportions of patients with negative spleen aspir- cesses on day 2 1. A relapse occurred in 2 patients in 
ates were compared within and between each group by group la (one on day 90 and one on day 180), one in 
calculating ~2; odds ratios (OR) and 95% confidence in- group lb on day 90 (who became negative again on day 
tervals (95% CI) were also calculated. The distribution of 180); and 2 in group lc (one on day 90 and one on day 
‘cures’ by visit was assessed and the results compared 180). 
with the aid of the Mantel-Haenszel test. A stratified Conversely, of the 48 atients who reported for at least 
analysis was conducted to compare the success rates in one follow-up visit, 9 w ifi o had been ‘failures’ at the end 
ktafe;minosidine groups and OR and 95% CI were cal- of therapy subsequently provided a negative spleen aspir- 
ate: 2 each in groups la and lc, and 4 in group lb. 
Paired observations of spleen and liver size and haema- Clinical assessment. Most patients improved clinically 
tological and blood chemistry data were compared at the 
baseline and on day 2 1 using the Kruskall-Wallis H test. 
on treatment. Considering all patients, paired observa- 
tions showed a significant decrease in spleen size from 
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8.3 cm (standard deviation [SD] 3.4) to 4 cm (SD 3) 
(P<O.OOl) and a substantial, though non-statistically sig- 
nificant, decrease in liver size (from 3.9 cm (SD 2) to 0.5 
cm (SD 1)). 
All patients had a palpable spleen before starting treat- 
ment; in 11 of them, the spleen was no longer palpable 
by the end of treatment, with no difference between 
groups. Comparing paired measurements of spleen size 
at baseline and on dav 2 1, a statisticallv significant reduc- 
tion was observed in-treatment groups 1; (P=O.O3) and 
lb (P=O.O2), but not in group lc (P=O.l). However, no 
statistically significant difference in spleen size reduction 
was observed between the groups. 
Similar findings were obtained with liver size. No stat- 
istically significant difference was found in or between 
the groups when comparing baseline and day 21. At 
baseline, 6 patients, 3 in group la, 2 in group lb and one 
in group lc, had a non-palpable liver. On day 2 1, the liver 
was not palpable in 24,27 and 21 patients, respectively. 
Most patients were afebrile by the end of therapy. All 
had intermittent fever before starting treatment, al- 
though a proportion of them had no fever at baseline. 
Clinical laboratory results. Overall, WBC counts in- 
creased from a mean of 3436.6~103imm3 (SD 1280.7~ 
103, range 1340x 103-8000~ 103) at the baseline to 
4810.6~ 103imm3 (SD 1678.37~ 103, range 2000x 103- 
10400x 103) at the end of therapy. No statistically signifi- 
cant difference was apparent among the groups when 
paired observations before and after treatment were com- 
pared for each patient. However, there were significantly 
more natients with WBC counts within the normal limits 
after treatment han at the baseline (OR= 15.52; 95% CI 
32.1660.09). Almost all patients had low haemoglobin 
values at baseline and they remained low after therapy. 
Total protein increased significantly on treatment from 
8.9 g/dL (SD 1.7) at baseline to 9.2 g/dL (SD 1.5) at the 
end of therapy. However, most patients had normal pre- 
treatment values. 
Tolerability. All 3 regimens were equally well tolerated, 
and with no patient was treatment discontinued due to an 
adverse vent. 
Of the 96 patients treated, 11 (11%) experienced 15 ad- 
verse events. Four patients (13%) in group la reported 5 
adverse events: 3 affected the gastrointestinal system (ab- 
dominal pain, nausea and gastrointestinal haemorrhage), 
one the nervous system (giddiness), and one was a breast 
abscess. Two patients (6%) in group lb reported 3 ad- 
verse events: one abdominal pain, one gastroenteritis and 
one case of fever. Five patients (16%) in group lc re- 
ported 7 adverse events: 3 cases of abdominal pain, one 
of vomiting, 2 cases of hearing disturbance and one case 
of herpes infection. One patient in groups la and lb and 
2 patients in group lc reported 2 adverse events each. 
Only one adverse event was reportedly severe but not 
drug-related; this occurred in group la. 
No renal toxicity was apparent. At the baseline, most 
patients had creatinine and blood urea nitrogen (BUN) 
values falling within the normal limits; posy-treatment 
values of creatinine and BUN remained unchaneed from 
the pre-treatment values. The mean creatinine level was 
1.02 mg/dL (SD 0.57) at the baseline and 0.79 (SD 0.36) 
after treatment: the corresoondine values for BUN were 
10.07 mg/dL (SD 4.56) andlO. mg/dL (SD 3.83). 
A significant increase in serum levels was observed for 
liver enzymes (alanine and aspartate aminotransferases, 
ALT and AST) in the naired observations. Also. sienifi- 
cantly more abnormal-values were observed on diy 21 
than at the baseline. The ORs for increased values after 
treatment were 3.69 (95O/, CI 1.35-10.05) for ALT and 
4.65 (95% CI 1.87-11.55) for AST. 
No abnormality in the ECG and no change in hearing 
was found after treatment, although audiometry was per- 
formed in only about 10% of the subjects. 
Aminosidine at 6 mgikgld (group 2) 
Patient enrolment was stopped after 40 patients had 
entered the study, owing to inadequacy of the treatment. 
The patient’s baseline characteristics (Table 1) did not 
differ significantly between the subgroups. 
Test of cure. The success rate at the end of therapy was 
marginally better in group 2a than in groups 2b and 2c 
(Table 2). 
Twenty-four and 12 patients were followed up for 90 
and 180 d, respectively; 13 and 7 were classified as treat- 
ment success at the end of therapy. A relapse occurred 
on day 90 in one patient in group 2c and one in group 2a, 
and on day 180 for one patient in group 2a and one in 
group 2b. 
- _ 
Of the 24 patients with at least one follow-up visit, 5 
treatment failures on day 21 (2, 4 and one in groups 2a, 
2b and 2c, respectively) had negative spleen aspirates 
after completion of their treatment. 
Clinical laboratorv results. WBC counts and haemo- 
globin levels increased, though not significantly, durin 
5 treatment: mean WBC counts were 3758.75 cells/mm 
(SD 1256.6) at the baseline and 4384.2 (SD 1684.15) at the 
end of therapy; haemoglobin values were 8.68 g/dL (SD 
1.86) at the baseline and 10.2 g/dL (SD 1.64) on day 21. 
No difference was apparent between the treatment sub- 
groups. 
Tolerability. Four adverse events occurred, 2 in group 
la and 2 in group lc. No statistically significant dif- 
ference was detected between the paired observations at 
the baseline and after treatment for all variables tested. 
Between-study comparison (aminosidine 12 mglkgld versus 6 
mglkgld) 
Patients assigned to receive aminosidine at 6 mgikgid 
were similar to those enrolled in the 12 mglkgid study 
(Table 1). 
The overall cure rate at end of therapy was 76% 
(73/95) with aminosidine at 12 mgikgld, while it was 55% 
(21/38) with aminosidine at 6 mgikgid (Table 2). The dif- 
ference in cure rates was statistically significant (x2 test, 
P=O.O14). Overall, patients receiving aminosidine at 12 
mgikgid had a 2.69 (95% CI 1.1-6.4) better chance of 
having a negative splenic aspirate at the end of therapy 
than did those treated with 6 me/k&d. Similarlv. at the 
end of therapy, stratified analy& Ef the numb&s with 
negative aspirates among those receiving aminosidine at 
12 mgikgid compared with the numbers-among those re- 
ceiving 6 ma/kg/d gave an OR=2.81 (95% CI 1.15-6.91) 
(P=o.-o22).- - - 
By contrast, comparison of distribution of negative as- 
pirates at successive xaminations in the group deceiving 
aminosidine at 12 maikaid with that amona those receiv- 
ing 6 mgikgld showed-substantial, though non-signifi- 
cant, differences. The relevant ORs were 3.07 (95% CI 
0.95-10.47) with sodium stibogluconate at 20 mg/kg/d, 
2.17 (95% CI 0.71-6.8 9) with sodium stibogluconate at 
10 mgikgid, and 2.8 (95% CI 0.9-9.02) with sodium sti- 
bogluconate at 5 mgikgid. 
No difference was observed in the incidence of adverse 
events in patients receiving the 2 aminosidine dosages, 
nor was any dose-related toxicity apparent with either 
drug. Treatment was generally acceptable in spite of the 
quite large volumes injected intramuscularly. 
Discussion 
The aim of this trial was to assess whether a combina- 
tion of aminosidine and antimony for a shorter duration 
could substitute for conventional, prolonged antimony 
and if so what were the limits of the combination in 
terms of efficacy and safety. The trial was therefore de- 
signed to identify effective and safe drug regimens and 
the sample size was calculated so as to enable identifica- 
tion of major differences among treatments. 
Aminosidine alone is active in vitro on L. donovani, 
with no cross-resistance with antimonial drugs: the two 
drugs act synergistically (S. Croft, personal communica- 
tion). However, aminosidine and sodium stibogluconate 
were only additive when tested in vivo in a mouse model 
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(MCCOY & NEAL, 1989). The antileishmanial action of 
aminosidine is thought to be related to misreading of 
messenger ribonucleic acid (EDLIND, 1991); the target of 
pentavalent antimonials is also not known precisely, al- 
though various mechanisms have been suggested (BER- 
MAN, 1988). At present, there is therefore no clear expla- 
nation for the synergistic action of these drugs in vitro. 
The slightly dissimilar results obtained in the experi- 
ments in vivo (MCCOY & NEAL, 1989), and partly con- 
firmed by our study, were probably due to the different 
pharmacokinetic profiles of the 2 drugs. 
Combined with antimony, aminosidine at 12 mgikgid 
was significantly more effective than at 6 mglkgid. By 
contrast, no difference was apparent between the various 
doses of sodium stibogluconate. When combined with 
aminosidine at either dose, some efficacy was seen even 
with 5 mglkgid of sodium stibogluconate for 20 d, a dose 
regimen that would be devoid of efficacy if given alone. 
When planning the experiment, we had decided to reject 
any dosage which was not 65% or more effective. Al- 
though aminosidine at 6 mg/kg/d +sodium stibogluco- 
nate at all doses used proved effective in 69% of cases, it 
was thought to be ethically necessary to close the study of 
this halved dose of aminisodine as the patients were 
clearly being offered less efficacious therapy. 
The aminosidine 12 mg/kg/d + sodium stibogluconate 
20 mglkgid regimen is preferred because, despite not 
achieving statistical significance, the results indicated 
that it was more active and no less safe than the other 
regimens. There was no obvious difference between the 
groups with respect to the other indicators of efficacy 
which we evaluated. 
Combination therapy with aminosidine has been tested 
clinically in 2 studies in Africa (CHUNGE et al.., 1990; 
SEAMAN et al., 1993) and in our pilot study m India 
(THAKUR et al., 1992). In both the Kenya and Sudan 
trials aminosidine was administered at 15 mgikgld in 
conjunction with sodium stibogluconate at 20 mglkgid 
for 14 and 15-17 d, respectively. The cure rates at the 
end of therapy were 100% and 95%, respectively. A 
drug-free follow-up was performed in Kenya, assessing 
the definite cure rate at 87%. In both studies, the combi- 
nation therapy was significantly more effective than so- 
dium stibogluconate alone. 
In Bihar, the cure rate at the end of therapy was 82% 
in the pilot study, and 88% both at the end of therapy 
and at follow-up with the maximum dose tested, amino- 
sidine 12 mg/kg/d and sodium stibogluconate 20 mgikgld 
for 20 d, in the current study. These results were re- 
markably consistent and similar to those obtained in 
Kenya with 2 weeks’ treatment including aminosidine at 
15 mg/kg/d. However, the cure rate in Bihar after 2 
weeksof-therapy was only 56% at best. It seems, there- 
fore, that treatment for 14-17 d with 15 mgikgid of ami- 
nosidine combined with 20 mglkgid of sodium stiboglu- 
conate is highly effective in African kala-azar but would 
be less likely to succeed in India. 
The combination of 14 malkeld aminosidine with so- 
dium stibogluconate 10 mg/kg/dYhas also proved effective 
and safe in a limited number of patients with diffuse 
cutaneous leishmaniasis caused by L. aethiopica (see 
TEKLEMARIAM et al., 1994). 
Treatments were well tolerated and no dose-related 
toxicity was apparent. Only liver enzymes rose slightly 
on treatment, which is a probable sign of antimony tox- 
icitv. However, these 20 d courses with sodium stiboalu- 
conate did not result in any cardiac toxicity, which h:gh- 
lights an additional benefit of combining antimony and 
aminosidine and curtailing therapy. It is unfortunate 
that, for technical reasons, post-treatment audiograms 
could be performed on only a limited number of patients; 
the available data do not suggest ototoxicity. 
The principal flaw of this study might be seen in the 
drug-free follow-up. Despite contacting patients, travel- 
ling and eneral inconvenience prevented many from re- 
porting or the scheduled assessments. The late ‘cures’ B 
and relapses observed indicate the need for more strin- 
gent planning of follow-up visits in future studies, in- 
cluding provision of financial support for travelling and 
lost income. However, even with all the weaknesses of 
follow-up in the present study, the overall conclusions 
did not differ after including the available information on 
relanses and late successes. 
Based on our results and those reported elsewhere, we 
therefore conclude that at least 12 meikn of aminosidine 
should be given daily for 20 d whencombined with the 
standard dose of sodium stibogluconate for the treatment 
of Indian kala-azar. Under the conditions of our studv 
this regimen appears to be highly effective and well tol- 
erated. 
Further studies supported by the UNDP/World 
Bank/WHO Special Programme for Research and Train- 
ing in Tropical Diseases are being conducted in order to 
assess the efficacy and safety of aminosidine alone. An- 
other study is being planned to compare the combined 
treatment with standard antimonial therapy in the same 
patient population. 
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The Basics of Travellers’ Health 
Swiss Tropical Institute Base1 and the International Society for Tropical Medicine 
This short certificate course will be held in Base1 from 2629 June 1995. It is intended to prepare prof- 
essionals (doctors, senior nursing staff, educators, teachers, trainers and travel industry staff) to give advice 
to travellers and on the treatment of travel-related iseases, with the main emphasis on the tropics. 
The course will be taught in English and the fee is Swiss francs 550.- 
Applications must be received by 31 May 1995. Further information can be obtained from Mrs M. Slaoui, 
Swiss Tropical Institute, Socinstrasse 57, P.O. Box, CH-4002 Base& Switzerland; phone +41 61 284 82 80, 
fax +44 6127179 51, telex 96 25 08. 
Gender, Health and Technology 
Entries are required for the fifth IDRUTDR award on gender and tropical diseases. The award (Canadian 
$5000) will be given to the author or authors of the best paper on this subject. Ideally, the.papers hould 
focus on one or more of the TDR’s target diseases; they must be originul and not previous1 
be based either on secondary sources or original research. Previous winners of an IDR 
8 ~blzshed, but may 
/ DR award are not 
eligible. 
Papers must be written in English, French or Spanish and must have a brief summary in English; they 
should not exceed 30 typed, double-spaced A4 pages and must be submitted by 30 April 1996. It would be 
helpful if intending authors informed Dr Carol Vlassoff (address below) well in advance of the deadline. 
Papers should be submitted to Dr Carol Vlassoff, Manager, Gender and Tropical Diseases Task Force, 
TDRNHO, 1211 Geneva 27, Switzerland. 
